179 related articles for article (PubMed ID: 38315878)
21. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
22. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
23. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Castillo JJ; Xu L; Gustine JN; Keezer A; Meid K; Dubeau TE; Liu X; Demos MG; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2019 Nov; 187(3):356-363. PubMed ID: 31267520
[TBL] [Abstract][Full Text] [Related]
24. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
25. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ; Branagan AR; Sermer D; Flynn CA; Meid K; Little M; Stockman K; White T; Canning A; Guerrera ML; Kofides A; Liu S; Liu X; Richardson K; Tsakmaklis N; Patterson CJ; Hunter ZR; Treon SP; Sarosiek S
Blood; 2024 Feb; 143(7):582-591. PubMed ID: 37971194
[TBL] [Abstract][Full Text] [Related]
27. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ; Xu L
Br J Haematol; 2019 Jan; 184(2):242-245. PubMed ID: 30183082
[TBL] [Abstract][Full Text] [Related]
29. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Deshpande A; Munoz J
Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Castillo JJ; Meid K; Gustine JN; Leventoff C; White T; Flynn CA; Sarosiek S; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Branagan AR; O'Donnell E; Raje N; Yee AJ; Patterson CJ; Hunter ZR; Treon SP
Leukemia; 2022 Feb; 36(2):532-539. PubMed ID: 34531537
[TBL] [Abstract][Full Text] [Related]
31. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
Richardson K; Castillo JJ; Sarosiek SR; Branagan AR; Flynn CA; Meid K; Gustine JN; Liu X; Kofides A; Liu S; Wolf JL; Kacena KA; Patterson CJ; Guerrera ML; Tsakmaklis N; Treon SP; Hunter ZR
Blood Adv; 2024 May; 8(9):2133-2137. PubMed ID: 38237078
[No Abstract] [Full Text] [Related]
32. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Castillo JJ; Abeykoon JP; Gustine JN; Zanwar S; Mein K; Flynn CA; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; King R; Yang G; Hunter ZR; Advani RH; Palomba ML; Ansell SM; Gertz MA; Kapoor P; Treon SP
Br J Haematol; 2021 Feb; 192(3):542-550. PubMed ID: 33207010
[TBL] [Abstract][Full Text] [Related]
33. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Lim KJC; Tam CS
Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
[TBL] [Abstract][Full Text] [Related]
35. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
Moore DC
J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
37. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
39. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract][Full Text] [Related]
40.
Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
